Skip to main content

Table 3 Comparisons between both waves regarding the type of neuropathy and outcome

From: Characteristics of COVID and post COVID polyneuropathies in adults and pediatrics: an Egyptian sample

  

Neuropathy type

P

  

AIDP

AMSAN

Demyelinating with secondary axonal

CIDP like

 

Wave

1st wave

11 (47.8%)

5 (21.7%)

3 (13.0%)

4 (17.4%)

0.193

2nd wave

14 (73.7%)

3 (15.8%)

2 (10.5%)

0 (0.0%)

  

Outcome

P

  

Full improvement

Minimal improvement

No improvement and needed second treatment to improve

 

Wave

1st wave

14 (60.9%)

3 (13.0%)

6 (26.1%)

0.084

2nd wave

17 (89.5%)

0 (0.0%)

2 (10.5%)

  1. AIDP acute inflammatory demyelinating polyneuropathy, AMSAN acute motor sensory axonal neuropathy, CIDP chronic inflammatory demyelinating polyneuropathy